Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in

  News Archive

Preceyes Enters into Collaborations With NightstaRx and the University of Oxford
Saturday, March 12, 2016
Company has announced collaboration with Nightstar and University of Oxford for the development of a high-precision subretinal drug delivery technology.

PhoreMost and The Wistar Institute Collaborate to Identify New Druggable Targets
Friday, March 11, 2016
Company has announced collaboration with The Wistar Institute to identified and de-orphan novel targets in cancer, aging and the immune system.

Largest Genomic Study on Kidney Cancer Brings Hope for More Effective Treatments
Tuesday, March 08, 2016
Researchers at Baylor College of Medicine have found that a pathway called immune checkpoint was most active in a subtype of clear cell kidney cancer that is typically very aggressive.

Discovery of Likely Subtypes of Rare Childhood Brain Tumor Signals Diagnostic Advance
Saturday, March 05, 2016
Researchers at St. Jude Children’s Research Hospital and German Cancer Research Center have identified that the molecular analysis is likely to improve classification and diagnosis of a rare brain tumor and advance precision medicine.

Rosetta Genomics Receives Approval
Friday, March 04, 2016
Company has announced conditional approval status for RosettaGX Reveal™, its novel microRNA classifier for the diagnosis of indeterminate thyroid fine needle aspirate.

Albumedix Announces Exclusive Commercialization Agreement with ThioLogics
Friday, March 04, 2016
Company has announced agreement with ThioLogics to commercialize the next generation of stable albumin drug conjugates.

New Drug Delivery Method for Pancreatic Cancer
Friday, March 04, 2016
UCLA researchers use nanoparticles to send chemotherapy drug directly to the tumor site, reducing damage to healthy tissues.

MDxHealth Announces Inclusion of ConfirmMDx in 2016 NCCN Guidelines for Prostate Cancer Early Detection
Thursday, March 03, 2016
Company has announced the guidelines provide recommendations to ensure that patients receive diagnostic testing services and treatment that have been shown to improve clinical outcomes.

Dicerna Reports Progress with GalNAc-DsiRNA-EX-Conjugates
Thursday, March 03, 2016
Dicerna has presented preclinical data suggesting the feasibility of its proprietary GalNAc-DsiRNA-EX-Conjugate technology in enabling direct delivery of RNAi-based therapy to the liver via subcutaneous (SC) or intravenous (IV) injection.

<< 7 8 9 10 11 12 13 >>
Showing Results 91 - 100 of 4058

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos